Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 16/20 | 0.35 |
| ▸ | JAK3 | P52333 | 15/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 13/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19949 | 0.86 | CD38 (0.40) | SYKEIF2AK4JAK2JAK3PTK2 | |
| SCHEMBL19253 | 0.84 | SYK (0.41) | SYKJAK2JAK3PTK2KDR | |
| SCHEMBL19957 | 0.83 | JAK2 (0.47) | JAK2JAK3PTK2 | |
| SCHEMBL15207957 | 0.82 | JAK2 (0.42) | SYKEIF2AK4JAK2JAK3PTK2 | |
| SCHEMBL21741 | 0.81 | SYK (0.39) | SYKEIF2AK4JAK2JAK3PTK2 | |
| SCHEMBL15207717 | 0.81 | JAK2 (0.48) | SYKEIF2AK4JAK2JAK3PTK2 | |
| SCHEMBL19314 | 0.81 | GSK3A (0.38) | SYKEIF2AK4JAK2JAK3PTK2 | |
| SCHEMBL19987 | 0.81 | KCNH2 (0.42) | JAK2JAK3PTK2 | |
| SCHEMBL19667 | 0.80 | SYK (0.39) | SYKEIF2AK4JAK2JAK3PTK2 | |
| SCHEMBL20134 | 0.80 | SYK (0.36) | SYKEIF2AK4JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| EP-2609098-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | SYK 1/4885EIF2AK4 1898/4885JAK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.